Alpha-9 Oncology reports initial dosing of the first participant in a phase 1 trial for A9-3202, targeting locally advanced or metastatic melanoma patients.

Atsena Therapeutics Reveals Encouraging Results from Initial Group in Phase 1/2 Study of ATSN-201 Gene Treatment for X-linked Retinoschisis (XLRS).

EyeDNA Therapeutics Reveals Encouraging Two-Year Results at ARVO for its Phase 1/2 Study on HORA-PDE6b Genetic Treatment in Retinitis Pigmentosa Patients with Dual Mutations in PDE6b.

Adcentrx Therapeutics has received IND approval from China's NMPA for ADRX-0706, a new Nectin-4 antibody-drug conjugate designed to treat advanced solid tumors.

Modalis Therapeutics Announces Promising Results for MDL-101, a Novel Epigenome Editing Treatment for LAMA2 Congenital Muscular Dystrophy (LAMA2-CMD).

Inmagene Announces Encouraging Early Outcomes of Phase 2a Study on IMG-007, a Nondepleting Anti-OX40 Monoclonal Antibody, Prolonged Duration, Aimed at Treating Atopic Dermatitis.

Boehringer Ingelheim has revealed encouraging results from its HORNBILL Phase I/IIa trial for BI 764524.

BioAtla Receives FDA Approval to Begin Trials of BA3361, a Conditionally Active Biologic (CAB) Targeting Nectin-4 in Various Cancers.

Mediar Initiates Clinical Stage for Its Unique Fibrosis Collection with Initial Group Treatment in Phase 1 Study of MTX-463, and Forms a Clinical Advisory Committee.

GIBF commits $10 million in funding to Nectin Therapeutics for the development of innovative first-in-class immunotherapies and antibody-drug conjugates.

Edgewise Therapeutics has administered the initial dose to a participant in the Phase 2 CIRRUS-HCM study, evaluating EDG-7500 in patients with Obstructive Hypertrophic Cardiomyopathy (HCM).

Fate Therapeutics Reveals FT522 Early-Stage Data on Autoimmune Disorders in a New Abstract at the ASGCT Annual Conference.